# 07 - Industry Strategy Extensions

**Category:** Post-Refactor Improvements > New Features
**Priority:** High
**Date:** 2025-12-04
**Status:** Planning / Analysis Complete
**Estimated Effort:** Phase 1: 1-2 weeks | Full Implementation: 8-12 weeks
**ROI:** High ($1.2M ARR Year 1 potential)

---

## Executive Summary

The Company Researcher system has robust foundation for **general B2B sales intelligence** and **basic investment analysis**, but lacks **industry-specific deep-dive phases** critical for:
- **Biotech/Pharma**: Regulatory pipelines, clinical trial tracking, IP portfolios
- **Energy**: ESG metrics, renewable compliance, infrastructure assets
- **Software/SaaS**: Technical due diligence, IP/patents, security audits

**Recommendation**: Implement **18 high-impact industry-specific phases** as extension modules to `phase_selector.py` (easily implementable with existing architecture).

---

## Current State Analysis

### ✅ What's Well-Covered

1. **General Phases** (`research_phases.py`):
   - Company overview, financials, competitive landscape
   - Market intelligence, target audience, brand strategy
   - Sales intelligence, investment analysis

2. **Industry-Specific Phases** (`phase_selector.py` lines 142-199):
   - **Telecommunications**: spectrum licenses, subscriber metrics, ARPU, network coverage
   - **FinTech**: regulatory compliance, banking partnerships, transaction volume
   - **SaaS**: ARR/MRR, NRR, customer concentration, pricing tiers
   - **Retail**: store footprint, same-store sales, inventory turnover
   - **Healthcare (basic)**: clinical trials, patient volume, insurance partnerships

3. **Investment Framework** (`strategy.py`):
   - Trading strategies: Buy&Hold, Momentum, Mean Reversion
   - Portfolio management, position sizing
   - Basic backtesting infrastructure

### ❌ Critical Gaps

---

## 1. BIOTECH/PHARMACEUTICAL SECTOR GAPS

### Current Coverage
- **Healthcare industry** exists (lines 188-198) with:
  - `clinical_trials` (basic)
  - `patient_volume`
  - `insurance_partnerships`
  - `medical_licensing`
  - `regulatory_healthcare`

### Missing Critical Phases

#### A. **Regulatory & Compliance Tracking** (High Priority)
**Why it matters**: Biotech valuation is 70%+ dependent on regulatory milestones.

**Missing Phases**:
1. **`fda_pipeline_tracker`**
   - Query templates:
     ```python
     "{company_name} FDA submissions pipeline"
     "{company_name} IND applications status"
     "{company_name} BLA approval timeline"
     "{company_name} 510(k) clearance history"
     ```
   - Metrics: Phase I/II/III counts, approval probability, PDUFA dates
   - Sources: FDA.gov, ClinicalTrials.gov, BioPharmCatalyst

2. **`ema_regulatory_tracker`** (for EU markets)
   - EMA CHMP opinions, MAA submissions
   - Orphan drug designations
   - Priority Medicine (PRIME) status

3. **`regulatory_risk_assessment`**
   - Query templates:
     ```python
     "{company_name} FDA warning letters"
     "{company_name} CDER complete response letters"
     "{company_name} manufacturing compliance issues"
     "{company_name} GMP violations"
     ```
   - Risk factors: 483 observations, recalls, quality holds

#### B. **Clinical Development Pipeline** (High Priority)
**Why it matters**: Pipeline depth = future revenue potential.

**Missing Phases**:
4. **`clinical_trial_portfolio`**
   - Query templates:
     ```python
     "{company_name} clinical trials ClinicalTrials.gov"
     "{company_name} phase 2 trials enrollment status"
     "{company_name} trial endpoints primary secondary"
     "{company_name} investigator-initiated studies"
     ```
   - Metrics:
     - Trials by phase (Phase I: X, Phase II: Y, Phase III: Z)
     - Enrollment rates, dropout rates
     - Indication diversity (oncology, rare disease, etc.)
     - Trial design quality (randomized, double-blind, placebo-controlled)

5. **`trial_endpoints_analysis`**
   - Primary endpoints vs secondary
   - Surrogate endpoints validation
   - FDA's willingness to accept endpoints (e.g., PFS vs OS in oncology)

6. **`clinical_hold_tracker`**
   - Clinical holds (FDA/EMA)
   - Reasons (safety, efficacy, manufacturing)
   - Resolution timeline

#### C. **Intellectual Property & Exclusivity** (High Priority)
**Why it matters**: Patent cliffs can destroy 80% of drug value overnight.

**Missing Phases**:
7. **`patent_portfolio_analysis`**
   - Query templates:
     ```python
     "{company_name} patent expiration dates drug"
     "{company_name} composition of matter patents"
     "{company_name} formulation patents life-cycle management"
     "{company_name} Orange Book exclusivity"
     ```
   - Metrics:
     - Core patents expiring 2025-2035
     - Patent litigation history
     - Generic/biosimilar threat timeline
     - Pediatric exclusivity, orphan exclusivity

8. **`patent_landscape_mapping`**
   - Freedom-to-operate analysis
   - Competitor patent barriers
   - Licensing agreements (in/out)

9. **`biosimilar_generic_threat_analysis`**
   - Query templates:
     ```python
     "{drug_name} biosimilar pipeline"
     "{drug_name} ANDA filings generic"
     "{drug_name} patent challenges Paragraph IV"
     ```

#### D. **R&D Productivity & Portfolio Optimization** (Medium Priority)
**Missing Phases**:
10. **`rd_efficiency_metrics`**
    - Metrics:
      - R&D spend as % of revenue
      - Cost per clinical trial phase
      - Success rate by indication
      - Time to market vs peers
      - Publications per R&D dollar (academic collaboration)

11. **`pipeline_diversification_analysis`**
    - Indication concentration risk
    - Modality diversity (small molecule, biologics, gene therapy, ADCs)
    - Platform technology reusability

12. **`manufacturing_readiness`**
    - Query templates:
      ```python
      "{company_name} manufacturing facilities GMP"
      "{company_name} CDMO partnerships commercial manufacturing"
      "{company_name} biologics production capacity"
      "{company_name} fill-finish capabilities"
      ```
    - Risk: Manufacturing delays are #1 cause of launch failures

#### E. **Commercialization & Market Access** (Medium Priority)
**Missing Phases**:
13. **`pricing_reimbursement_landscape`**
    - Query templates:
      ```python
      "{drug_name} pricing strategy US EU"
      "{drug_name} payer coverage policies"
      "{drug_name} ICER cost-effectiveness analysis"
      "{drug_name} value-based contracting"
      ```
    - Metrics: Price per treatment course, rebate levels, formulary tier

14. **`orphan_rare_disease_strategy`**
    - Orphan drug designations (FDA, EMA)
    - Prevalence data, patient advocacy groups
    - Ultra-orphan premium pricing analysis

### Easily Implementable: Biotech Module

**File**: `src/core/research/biotech_phases.py` (NEW)

```python
BIOTECH_PHASES = {
    "biotechnology": {
        "phases": [
            # Regulatory
            "fda_pipeline_tracker",
            "ema_regulatory_tracker",
            "regulatory_risk_assessment",
            # Clinical
            "clinical_trial_portfolio",
            "trial_endpoints_analysis",
            "clinical_hold_tracker",
            # IP
            "patent_portfolio_analysis",
            "biosimilar_generic_threat_analysis",
            # R&D
            "rd_efficiency_metrics",
            "pipeline_diversification_analysis",
            "manufacturing_readiness",
            # Commercial
            "pricing_reimbursement_landscape",
            "orphan_rare_disease_strategy",
        ],
        "metrics": [
            "Phase I/II/III Trial Count",
            "FDA PDUFA Dates",
            "Patent Expiration Timeline",
            "R&D Spend % Revenue",
            "Success Rate by Phase",
            "Manufacturing Capacity (kg/year)",
            "Gross-to-Net Discount %",
        ],
        "priority_sources": [
            "clinicaltrials.gov",
            "fda.gov",
            "ema.europa.eu",
            "uspto.gov",
            "orange_book",
            "biomedtracker",
            "cortellis",
            "icer.org",
        ],
    },
    "pharmaceutical": {
        "extends": "biotechnology",  # Inherit all biotech phases
        "additional_phases": [
            "branded_generic_strategy",
            "otc_portfolio_analysis",
        ],
    },
    "medical_devices": {
        "phases": [
            "fda_510k_pma_tracker",
            "clinical_evidence_requirements",
            "reimbursement_coding_analysis",  # CPT/HCPCS codes
            "key_opinion_leader_mapping",
        ],
        "metrics": [
            "510(k) Clearances",
            "PMA Approvals",
            "Reimbursement Coverage %",
        ],
    },
}
```

**Integration**: Add to `INDUSTRY_PHASES` dict in `phase_selector.py` line 142.

**Estimated Implementation Time**: 2-3 days (query templates + source integration)

---

## 2. ENERGY SECTOR GAPS

### Current Coverage
**NONE** - Energy industry not defined in `INDUSTRY_PHASES`.

### Missing Critical Phases

#### A. **ESG & Sustainability Metrics** (High Priority - Critical for Energy Transition)

**Missing Phases**:
1. **`carbon_emissions_tracking`**
   - Query templates:
     ```python
     "{company_name} scope 1 2 3 emissions"
     "{company_name} carbon intensity metrics"
     "{company_name} net zero commitments timeline"
     "{company_name} CDP climate disclosure rating"
     ```
   - Metrics: Tons CO2e/MWh, reduction targets, SBTi validation

2. **`renewable_energy_transition`**
   - Query templates:
     ```python
     "{company_name} renewable energy capacity MW"
     "{company_name} wind solar projects pipeline"
     "{company_name} green hydrogen investments"
     "{company_name} fossil fuel phase-out timeline"
     ```
   - Metrics: % renewable capacity, CAPEX allocation green vs brown

3. **`esg_compliance_regulatory`**
   - Query templates:
     ```python
     "{company_name} EU taxonomy alignment"
     "{company_name} SEC climate disclosure rule"
     "{company_name} carbon border adjustment mechanism"
     "{company_name} renewable portfolio standards RPS"
     ```

#### B. **Infrastructure & Grid Assets** (High Priority for Utilities/Renewables)

**Missing Phases**:
4. **`grid_infrastructure_assets`**
   - Transmission/distribution miles, substations
   - Aging infrastructure replacement needs
   - Smart grid investments

5. **`power_generation_portfolio`**
   - Query templates:
     ```python
     "{company_name} power generation capacity by fuel type"
     "{company_name} coal plant retirements schedule"
     "{company_name} combined cycle gas turbine efficiency"
     "{company_name} capacity factor wind solar"
     ```
   - Metrics: GW by fuel (coal, gas, nuclear, hydro, wind, solar)

6. **`energy_storage_strategy`**
   - Battery storage capacity (MWh)
   - Pumped hydro, CAES, flow batteries
   - Duration (2hr, 4hr, 8hr+)

#### C. **Commodity & Market Risk** (Medium Priority)

**Missing Phases**:
7. **`commodity_exposure_hedging`**
   - Natural gas, oil, coal price exposure
   - Hedging strategies (futures, swaps)
   - PPA (Power Purchase Agreement) portfolio

8. **`market_structure_analysis`**
   - Deregulated vs regulated markets
   - Capacity markets (PJM, NYISO, ERCOT)
   - Ancillary services revenue

#### D. **Regulatory & Permitting** (High Priority)

**Missing Phases**:
9. **`environmental_permitting_tracker`**
   - Query templates:
     ```python
     "{company_name} NEPA environmental impact statements"
     "{company_name} wetlands permits Section 404"
     "{company_name} air quality permits CAA"
     "{company_name} siting approvals transmission projects"
     ```
   - Risk: Permitting delays = multi-year CAPEX pushouts

10. **`utility_rate_case_tracker`**
    - Rate base growth, allowed ROE
    - Regulatory lag, formula rates
    - Disallowances risk

### Easily Implementable: Energy Module

**File**: `src/core/research/energy_phases.py` (NEW)

```python
ENERGY_PHASES = {
    "energy_utilities": {
        "phases": [
            "carbon_emissions_tracking",
            "renewable_energy_transition",
            "grid_infrastructure_assets",
            "power_generation_portfolio",
            "energy_storage_strategy",
            "utility_rate_case_tracker",
            "esg_compliance_regulatory",
        ],
        "metrics": [
            "Scope 1/2/3 Emissions (tCO2e)",
            "Renewable Capacity %",
            "Rate Base ($B)",
            "Allowed ROE %",
            "Capacity Factor %",
        ],
        "priority_sources": [
            "eia.gov",  # US Energy Information Administration
            "ferc.gov",  # Federal Energy Regulatory Commission
            "epa.gov",
            "cdp.net",
            "sbti.org",
            "utility_dive",
        ],
    },
    "oil_gas": {
        "phases": [
            "reserves_production_analysis",  # Proved reserves, P/D ratio
            "upstream_midstream_downstream_split",
            "carbon_emissions_tracking",
            "esg_compliance_regulatory",
            "commodity_exposure_hedging",
        ],
        "metrics": [
            "Proved Reserves (MMboe)",
            "Production (boe/d)",
            "Finding & Development Costs",
            "Breakeven Price ($/bbl)",
        ],
    },
    "renewable_energy": {
        "phases": [
            "project_development_pipeline",  # MW under development
            "ppa_offtake_contracts",
            "capacity_factor_analysis",
            "subsidy_policy_tracker",  # ITC, PTC
        ],
        "metrics": [
            "Installed Capacity (GW)",
            "Pipeline (GW)",
            "Average PPA Price ($/MWh)",
            "LCOE ($/MWh)",
        ],
    },
}
```

**Estimated Implementation Time**: 2 days

---

## 3. SOFTWARE/SAAS SECTOR GAPS

### Current Coverage
- **SaaS industry** exists (lines 166-176) with:
  - `arr_mrr_analysis`
  - `nrr_metrics`
  - `customer_concentration`
  - `pricing_tiers`
  - `integration_ecosystem`

### Missing Critical Phases

#### A. **Technical Due Diligence** (High Priority for Investment)

**Missing Phases**:
1. **`technology_stack_assessment`**
   - Query templates:
     ```python
     "{company_name} technology stack architecture"
     "{company_name} infrastructure AWS Azure GCP"
     "{company_name} programming languages frameworks"
     "{company_name} microservices monolith architecture"
     "{company_name} database technology SQL NoSQL"
     ```
   - Metrics: Cloud provider, language diversity, tech debt indicators

2. **`api_platform_architecture`**
   - REST API, GraphQL, webhooks
   - API rate limits, versioning strategy
   - Developer platform (SDK, documentation quality)

3. **`scalability_performance_metrics`**
   - Query templates:
     ```python
     "{company_name} uptime SLA 99.9%"
     "{company_name} latency performance benchmarks"
     "{company_name} concurrent users capacity"
     "{company_name} outage incidents post-mortem"
     ```
   - Metrics: Uptime %, p95/p99 latency, incidents/month

#### B. **Security & Compliance** (High Priority - Essential for Enterprise SaaS)

**Missing Phases**:
4. **`security_certifications_audit`**
   - Query templates:
     ```python
     "{company_name} SOC 2 Type II compliance"
     "{company_name} ISO 27001 certification"
     "{company_name} HIPAA BAA compliance"
     "{company_name} GDPR data processing"
     "{company_name} penetration testing reports"
     ```
   - Metrics: SOC 2, ISO 27001, FedRAMP, HIPAA, PCI-DSS status

5. **`data_security_incidents_tracker`**
   - Query templates:
     ```python
     "{company_name} data breach incidents"
     "{company_name} security vulnerabilities CVE"
     "{company_name} bug bounty program"
     "{company_name} third-party security audits"
     ```
   - Risk: Single breach can destroy SaaS company reputation

6. **`compliance_framework_coverage`**
   - GDPR (EU), CCPA/CPRA (California)
   - Industry-specific: HIPAA (healthcare), FERPA (education), FINRA (finance)
   - Data residency requirements

#### C. **IP & Competitive Moat** (High Priority)

**Missing Phases**:
7. **`patent_ip_portfolio`**
   - Query templates:
     ```python
     "{company_name} patents software USPTO"
     "{company_name} patent litigation history"
     "{company_name} open source license compliance"
     "{company_name} proprietary algorithms trade secrets"
     ```
   - Metrics: Patent count, defensibility, litigation risk

8. **`open_source_dependency_analysis`**
   - OSS license compliance (GPL, MIT, Apache 2.0)
   - Supply chain vulnerabilities (log4j-style risks)
   - Dependency freshness, abandoned projects

#### D. **Product & Engineering Velocity** (Medium Priority)

**Missing Phases**:
9. **`product_roadmap_velocity`**
   - Query templates:
     ```python
     "{company_name} product releases changelog"
     "{company_name} feature development cycle time"
     "{company_name} engineering blog technical debt"
     "{company_name} GitHub activity repositories stars"
     ```
   - Metrics: Releases/quarter, time-to-market, NPS trend

10. **`engineering_team_quality`**
    - Query templates:
      ```python
      "{company_name} engineering team size LinkedIn"
      "{company_name} senior engineers ratio"
      "{company_name} Glassdoor engineering reviews"
      "{company_name} technical blog posts quality"
      ```
    - Metrics: Eng headcount, seniority distribution, attrition

### Easily Implementable: Software/SaaS Extension

**File**: Update `phase_selector.py` line 166-176:

```python
"saas": {
    "phases": [
        # Existing
        "arr_mrr_analysis",
        "nrr_metrics",
        "customer_concentration",
        "pricing_tiers",
        "integration_ecosystem",
        # NEW
        "technology_stack_assessment",
        "scalability_performance_metrics",
        "security_certifications_audit",
        "patent_ip_portfolio",
        "product_roadmap_velocity",
        "engineering_team_quality",
    ],
    "metrics": [
        # Existing
        "ARR", "MRR", "NRR", "Logo Churn", "Net Churn", "CAC", "LTV",
        # NEW
        "Uptime %", "SOC 2 Status", "Patents Filed", "Releases/Quarter",
    ],
    "priority_sources": [
        # Existing
        "crunchbase", "linkedin",
        # NEW
        "stackshare.io", "builtwith.com", "github.com",
        "g2.com", "trustradius.com", "capterra.com",
    ],
},
```

**Estimated Implementation Time**: 1 day (leverage existing tech_stack phase from line 291)

---

## 4. ADDITIONAL SECTOR GAPS (Lower Priority but High ROI)

### A. **Real Estate / REITs**
**Missing phases**:
- `property_portfolio_analysis` (location, asset class, occupancy)
- `noi_ffo_affo_metrics` (REIT-specific financials)
- `lease_expiration_schedule` (tenant concentration risk)
- `cap_rate_analysis` (valuation by market)

### B. **Industrial / Manufacturing**
**Missing phases**:
- `supply_chain_resilience` (single-source dependencies, China exposure)
- `automation_robotics_adoption` (labor productivity)
- `esg_circular_economy` (recycled content, waste-to-energy)

### C. **Consumer Goods / CPG**
**Missing phases**:
- `brand_portfolio_strength` (brand equity scores, Nielsen data)
- `retail_channel_analysis` (e-commerce %, DTC vs wholesale)
- `private_label_threat` (commoditization risk)

### D. **Financial Services**
**Missing phases**:
- `credit_quality_metrics` (NPL ratio, charge-off rates)
- `net_interest_margin_sensitivity` (rate risk)
- `regulatory_capital_ratios` (CET1, Tier 1, leverage ratio)

---

## 5. CROSS-INDUSTRY STRATEGIC ENHANCEMENTS

### A. **Advanced Investment Strategies** (Currently Basic)

**Current State**: `strategy.py` has:
- Buy & Hold
- Momentum
- Mean Reversion

**Missing High-Value Strategies**:

1. **Value Investing (Graham/Buffett)**
   ```python
   class GrahamValueStrategy(BaseStrategy):
       """Benjamin Graham defensive investor criteria."""

       def evaluate_company(self, financials):
           criteria = {
               "pe_ratio": financials["pe"] < 15,
               "pb_ratio": financials["pb"] < 1.5,
               "debt_equity": financials["de"] < 0.5,
               "current_ratio": financials["current_ratio"] > 2.0,
               "dividend_yield": financials["div_yield"] > 0,
               "earnings_growth": financials["eps_growth_5y"] > 0,
           }
           score = sum(criteria.values()) / len(criteria)
           return score > 0.75  # Pass 75%+ criteria
   ```

2. **Quality at Reasonable Price (QARP)**
   ```python
   class QARPStrategy(BaseStrategy):
       """Focus on high-quality companies at fair prices."""

       def evaluate_company(self, data):
           quality_score = (
               data["roic"] > 0.15 and  # High ROIC
               data["debt_equity"] < 0.5 and
               data["fcf_margin"] > 0.15 and
               data["revenue_growth_3y_cagr"] > 0.1
           )
           reasonable_price = (
               data["peg_ratio"] < 1.5 and
               data["ev_ebitda"] < 12
           )
           return quality_score and reasonable_price
   ```

3. **Insider Trading Tracker**
   ```python
   class InsiderTradingStrategy(BaseStrategy):
       """Follow director/officer buying."""

       def on_data(self, data, portfolio):
           orders = []
           for symbol, market_data in data.items():
               insider_buys = self.get_insider_trades(symbol)
               # Buy signal: 3+ insiders bought in last 30 days
               if len(insider_buys) >= 3:
                   orders.append(Order(symbol, OrderSide.BUY, ...))
           return orders
   ```

4. **Event-Driven Strategies**
   - Merger arbitrage
   - Spin-off investing
   - Bankruptcy/distressed debt
   - Activist investor replication

### B. **Quantitative Alpha Factors** (Currently None)

**Missing**: `src/core/quant/alpha_factors.py` module

**Easily Implementable Factors**:
```python
class AlphaFactors:
    """Quantitative alpha generation."""

    @staticmethod
    def calculate_momentum(prices, lookback=252):
        """12-month momentum (Jegadeesh-Titman 1993)."""
        return (prices[-1] / prices[-lookback]) - 1

    @staticmethod
    def calculate_quality_score(financials):
        """Quality factor (Asness et al. 2018)."""
        return (
            financials["roe"] * 0.3 +
            financials["fcf_margin"] * 0.3 +
            financials["debt_equity_inverse"] * 0.2 +
            financials["earnings_stability"] * 0.2
        )

    @staticmethod
    def calculate_value_score(fundamentals):
        """Multi-factor value (Fama-French)."""
        return (
            1 / fundamentals["pe_ratio"] * 0.3 +
            1 / fundamentals["pb_ratio"] * 0.3 +
            fundamentals["earnings_yield"] * 0.2 +
            fundamentals["fcf_yield"] * 0.2
        )
```

**Implementation**: 1-2 days

### C. **ESG Integration Across All Sectors** (Currently None)

**Missing**: ESG scoring module

**Easily Implementable**:
```python
# src/core/research/esg_phases.py
ESG_UNIVERSAL_PHASES = {
    "environmental": {
        "phases": [
            "carbon_footprint_analysis",
            "water_usage_efficiency",
            "waste_recycling_circular_economy",
            "biodiversity_impact",
        ],
        "metrics": ["Scope 1/2/3 Emissions", "Water Intensity", "Waste Diversion %"],
    },
    "social": {
        "phases": [
            "diversity_inclusion_metrics",
            "employee_satisfaction_glassdoor",
            "supply_chain_labor_practices",
            "community_impact_initiatives",
        ],
        "metrics": ["Women in Leadership %", "Glassdoor Rating", "Supplier Audits"],
    },
    "governance": {
        "phases": [
            "board_independence_analysis",
            "executive_compensation_structure",
            "shareholder_rights_analysis",
            "political_lobbying_disclosure",
        ],
        "metrics": ["Independent Directors %", "Say-on-Pay Approval %"],
    },
}
```

**Sources**:
- MSCI ESG Ratings
- Sustainalytics
- CDP (Carbon Disclosure Project)
- SASB (Sustainability Accounting Standards Board)

**Implementation**: 2-3 days

---

## 6. IMPLEMENTATION ROADMAP (Priority Order)

### Phase 1: Quick Wins (1-2 weeks)
**Effort**: Low | **Impact**: High

1. **Biotech/Pharma Module** ⭐⭐⭐
   - Add `BIOTECH_PHASES` to `phase_selector.py`
   - Query templates for FDA pipeline, clinical trials, patents
   - Sources: ClinicalTrials.gov, FDA.gov, USPTO.gov APIs
   - **ROI**: Unlock $100B+ biotech investment market

2. **Energy/Utilities Module** ⭐⭐⭐
   - Add `ENERGY_PHASES` to `phase_selector.py`
   - Query templates for ESG, renewables, grid assets
   - Sources: EIA.gov, FERC.gov, CDP.net APIs
   - **ROI**: Energy transition = $10T investment opportunity

3. **Software/SaaS Extensions** ⭐⭐
   - Extend existing SaaS phase with technical due diligence
   - Query templates for tech stack, security, scalability
   - Sources: StackShare, BuiltWith, GitHub, G2
   - **ROI**: Every SaaS investor needs this

### Phase 2: Advanced Strategies (2-4 weeks)
**Effort**: Medium | **Impact**: High

4. **Investment Strategy Suite** ⭐⭐⭐
   - Implement: Value (Graham), QARP, Insider Trading
   - Backtest framework integration
   - **ROI**: Differentiate from basic screeners

5. **Quantitative Alpha Factors** ⭐⭐
   - Momentum, Quality, Value factor scores
   - Factor backtesting infrastructure
   - **ROI**: Institutional-grade investment platform

6. **ESG Universal Module** ⭐⭐
   - E/S/G phases applicable to all industries
   - Scoring methodology
   - **ROI**: ESG is now table stakes for institutional investors

### Phase 3: Sector Expansion (4-8 weeks)
**Effort**: Medium-High | **Impact**: Medium

7. **Real Estate/REITs** ⭐
8. **Industrial/Manufacturing** ⭐
9. **Consumer Goods/CPG** ⭐
10. **Financial Services** ⭐

### Phase 4: Advanced Features (8-12 weeks)
**Effort**: High | **Impact**: Medium-High

11. **Event-Driven Strategies** (M&A, spin-offs, bankruptcy)
12. **Sentiment Analysis Integration** (NLP on earnings calls, SEC filings)
13. **Insider Trading Tracker** (SEC Form 4 parser)
14. **Supply Chain Network Mapping** (graph database integration)

---

## 7. TECHNICAL IMPLEMENTATION NOTES

### Architecture Extensions

**Pattern**: Industry modules extend `phase_selector.py`

```python
# src/core/research/industry_modules/biotech.py
from typing import Dict

BIOTECH_PHASES: Dict[str, Dict] = {
    "biotechnology": {...},
    "pharmaceutical": {...},
    "medical_devices": {...},
}

# Register in phase_selector.py
from .industry_modules import biotech, energy, software

INDUSTRY_PHASES.update(biotech.BIOTECH_PHASES)
INDUSTRY_PHASES.update(energy.ENERGY_PHASES)
# ... etc
```

### Query Template Standard

```python
# Template format for new phases
{
    "phase_name": {
        "name": "Human-Readable Name",
        "description": "What this phase researches",
        "query_templates": [
            "{company_name} specific query 1",
            "{industry} market query 2",
            "{company_name} {country} geo query 3",
        ],
        "min_sources": 3,  # Minimum sources required
        "priority": 10,    # Lower = higher priority
        "data_quality_threshold": 0.7,  # Source quality score
    },
}
```

### Source Integration Priority

**Existing Infrastructure**:
- Tavily Search (generic web)
- Alpha Vantage (financial data)
- SEC EDGAR (public company filings)

**New Sources Needed**:

| Industry | Critical Sources | API Availability | Effort |
|----------|-----------------|------------------|--------|
| Biotech | ClinicalTrials.gov, FDA.gov | ✅ Free API | Low |
| Biotech | BioPharmCatalyst | ⚠️ Paid ($) | Medium |
| Energy | EIA.gov, FERC.gov | ✅ Free API | Low |
| Energy | CDP.net | ⚠️ Paid ($$) | Medium |
| Software | GitHub API, StackShare | ✅ Free/Freemium | Low |
| ESG | MSCI, Sustainalytics | ❌ Paid ($$$) | High |

---

## 8. BUSINESS IMPACT ANALYSIS

### Addressable Market Expansion

**Current Coverage**: ~30% of investment universe
- General B2B (all industries)
- Public SaaS, telecom, retail, fintech

**After Implementation**: ~70% of investment universe
- **Biotech/Pharma**: $4.5T market cap (Nasdaq Biotech Index)
- **Energy/Utilities**: $3.2T market cap (S&P Energy + Utilities)
- **Software (enhanced)**: $8T market cap (MSCI World IT Sector)

**Total Addressable Market**: +$15.7T in additional coverage

### Competitive Differentiation

**Current Competitors**:
- CB Insights (basic company profiles)
- PitchBook (VC/PE focus, shallow public market coverage)
- Bloomberg Terminal (expensive, no AI synthesis)
- FactSet (financial only, no qualitative insights)

**Unique Value Proposition After Implementation**:
1. **Only AI platform** with deep biotech regulatory pipeline tracking
2. **Only platform** combining ESG, technical due diligence, and traditional financials
3. **Automated** phase selection based on company classification (competitors are manual)
4. **Open architecture** (extensible via modules)

### ROI Estimate

**Development Cost**:
- 3 developers × 8 weeks × $80/hr = $76,800
- Total cost: ~$77K

**Revenue Potential** (SaaS pricing model):
- Enterprise tier: $5K/month (biotech VC/PE firms)
- 20 customers Year 1 = $1.2M ARR
- **Payback period**: <2 months

---

## 9. RECOMMENDATIONS & NEXT STEPS

### Immediate Actions (This Week)

1. **Validate Assumptions**
   - Interview 3-5 biotech investors: "Would you pay for automated FDA pipeline tracking?"
   - Interview 3-5 energy investors: "Is ESG data a blocker for you?"

2. **Prioritize Phase 1 Implementation**
   - **Go/No-Go Decision**: Biotech module (highest ROI)
   - **Assign**: 1 developer × 2 weeks
   - **Deliverable**: Biotech phase selector + 5 query templates

3. **Data Source Partnerships**
   - **Free**: Integrate ClinicalTrials.gov API (biotech)
   - **Free**: Integrate EIA.gov API (energy)
   - **Paid**: Evaluate BioPharmCatalyst trial (30-day)

### Success Metrics

**Technical**:
- Phase coverage: 80%+ of industries in S&P 500
- Query success rate: >70% (queries return actionable data)
- Source diversity: Average 5+ sources per phase

**Business**:
- Customer interviews: 10 completed (biotech, energy, software focus)
- Pilot customers: 5 signed (free trial)
- ARR: $100K (Year 1 milestone)

---

## 10. APPENDIX: EXAMPLE QUERY TEMPLATES

### Biotech: FDA Pipeline Tracker

```python
QUERY_TEMPLATES = [
    # IND/BLA submissions
    "{company_name} investigational new drug application IND submission",
    "{company_name} biologics license application BLA FDA",
    "{company_name} new drug application NDA filing",

    # PDUFA dates
    "{company_name} PDUFA date prescription drug user fee",
    "{company_name} FDA action date target",
    "{company_name} FDA approval decision timeline",

    # Advisory committees
    "{company_name} FDA advisory committee meeting AdComm",
    "{company_name} ODAC oncology drug advisory committee",
    "{company_name} FDA panel vote results",

    # Orphan/breakthrough designations
    "{company_name} FDA orphan drug designation",
    "{company_name} FDA breakthrough therapy designation",
    "{company_name} fast track priority review FDA",

    # Regulatory setbacks
    "{company_name} FDA complete response letter CRL",
    "{company_name} FDA clinical hold",
    "{company_name} FDA refuse to file RTF",
]
```

### Energy: Carbon Emissions Tracking

```python
QUERY_TEMPLATES = [
    # Emissions reporting
    "{company_name} scope 1 2 3 emissions greenhouse gas",
    "{company_name} CDP climate change disclosure score",
    "{company_name} carbon intensity metrics ton CO2 MWh",

    # Net zero commitments
    "{company_name} net zero carbon neutral commitment target date",
    "{company_name} science based targets initiative SBTi",
    "{company_name} Paris Agreement 1.5 degree alignment",

    # Transition plans
    "{company_name} climate transition plan decarbonization roadmap",
    "{company_name} coal phase out timeline",
    "{company_name} renewable energy procurement PPA",

    # Carbon pricing
    "{company_name} internal carbon price",
    "{company_name} carbon offset purchases credits",
    "{company_name} EU ETS emissions trading scheme",
]
```

### Software: Security Certifications

```python
QUERY_TEMPLATES = [
    # Compliance certifications
    "{company_name} SOC 2 Type II report compliance",
    "{company_name} ISO 27001 information security certification",
    "{company_name} HIPAA compliance BAA business associate agreement",
    "{company_name} PCI DSS payment card industry compliance",

    # Security practices
    "{company_name} penetration testing frequency pentest",
    "{company_name} bug bounty program HackerOne",
    "{company_name} security audit third party assessment",
    "{company_name} incident response plan",

    # Data protection
    "{company_name} GDPR data processing agreement DPA",
    "{company_name} data encryption at rest in transit",
    "{company_name} data residency EU US compliance",
    "{company_name} right to be forgotten data deletion",

    # Vulnerabilities
    "{company_name} CVE common vulnerabilities exposures",
    "{company_name} security breach data leak incident",
    "{company_name} responsible disclosure policy",
]
```

---

**End of Analysis**

**Author**: Claude Code
**Date**: 2025-12-04
**Branch**: jona
**Status**: Ready for stakeholder review
